Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond Amplification: Precision Approaches to Targeting HER2.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2026

Lloyd Maxwell R, Pegram Mark D, Wander Seth A

Abstract excerpt

HER2-directed tyrosine kinase inhibitor combinations with trastuzumab represent an emerging strategy for hormone receptor-negative or -positive metastatic breast cancer with activating HER2 mutations. Correlative genomics reveal on-target and downstream molecular evolution during treatment, identifying response patterns and potential acquired resistance mechanisms. Refining precision therapies for HER2-mutant...

Read the complete abstract on PubMed

Topics

Humans
Erb-b2 Receptor Tyrosine Kinases
Breast Neoplasms
Trastuzumab
Molecular Targeted Therapy
Female

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Mutation

Precision Medicine

Drug Resistance, Neoplasm

Gene Amplification

Source

Identifiers

PMID: 42423636
DOI: 10.1158/1078-0432.CCR-26-1340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond Amplification: Precision Approaches to Targeting HER2.PMID 42423636Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Semantic proximity Read ↗

Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.Semantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.Semantic proximity Read ↗

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read ↗

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.